188 related articles for article (PubMed ID: 30111844)
41. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
[TBL] [Abstract][Full Text] [Related]
42. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
43. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy.
Moreno C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):33-40. PubMed ID: 33275679
[TBL] [Abstract][Full Text] [Related]
44. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
45. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
46. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
47. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia.
Mraz M; Kipps TJ
Leuk Lymphoma; 2013 Aug; 54(8):1836-9. PubMed ID: 23597135
[TBL] [Abstract][Full Text] [Related]
48. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
49. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
[TBL] [Abstract][Full Text] [Related]
50. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Fischer K; Bahlo J; Fink AM; Goede V; Herling CD; Cramer P; Langerbeins P; von Tresckow J; Engelke A; Maurer C; Kovacs G; Herling M; Tausch E; Kreuzer KA; Eichhorst B; Böttcher S; Seymour JF; Ghia P; Marlton P; Kneba M; Wendtner CM; Döhner H; Stilgenbauer S; Hallek M
Blood; 2016 Jan; 127(2):208-15. PubMed ID: 26486789
[TBL] [Abstract][Full Text] [Related]
51. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
52. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
[TBL] [Abstract][Full Text] [Related]
53. Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.
Thompson PA; Tam CS
Oncology (Williston Park); 2018 Jun; 32(6):291-2, 294-6. PubMed ID: 29940059
[No Abstract] [Full Text] [Related]
54. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
55. [The expression and prognostic significance of microRNA-34a in Uygur and Han patients with chronic lymphocytic leukemia in Xinjiang Uygur Autonomous Region in China].
Liu H; Wang XM; Mao M; Fu L; Huang Q; Wang YL; Wang YC; Wang ZS; Li Y
Zhonghua Nei Ke Za Zhi; 2018 Dec; 57(12):922-925. PubMed ID: 30486562
[TBL] [Abstract][Full Text] [Related]
56. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
[TBL] [Abstract][Full Text] [Related]
57. Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
Milne K; Sturrock B; Chevassut T
Curr Oncol Rep; 2020 Mar; 22(4):36. PubMed ID: 32172299
[TBL] [Abstract][Full Text] [Related]
58. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
Jain P; Lee HJ; Qiao W; Wierda W; Benjamini O; Burger J; Ferrajoli A; Estrov Z; Kantarjian H; Keating M; O'Brien S
Cancer; 2014 Nov; 120(22):3494-501. PubMed ID: 25043749
[TBL] [Abstract][Full Text] [Related]
59. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
60. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
